Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients

被引:52
作者
Hahn, Bevra H. [1 ]
Anderson, Marissa [1 ]
Le, Elizabeth [1 ]
La Cava, Antonio [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA
来源
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 08期
关键词
D O I
10.1002/art.23609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Treg cells oppose autoreactive responses in several autoimmune diseases, and their frequency is reduced in systemic lupus erythematosus (SLE). In murine lupus models, treatment with anti-DNA Ig-based peptides can expand the number of Treg cells in vivo. This study was undertaken to test the possibility that functional human Treg cells can be induced by exposure to anti-DNA Ig-based peptides. Methods. Peripheral blood mononuclear cells were isolated from 36 lupus patients and 32 healthy individuals matched for ethnicity, sex, and age. Shortterm culture experiments in the presence of several independent stimuli including anti-DNA Ig peptides were followed by flow cytometric analysis for identification of CD4+,CD25(high) T cells, cell sorting for in vitro suppression assays, and analysis of correlations between the expression of forkhead box P3 (FoxP3) and serologic and clinical characteristics of the SLE patients. Results. The number of in vitro CD4+,CD25(high) T cells increased after culture with anti-DNA Ig peptides in the SLE patients, but not in the controls. The expanded CD4+,CD25(high) T cells required FoxP3 for cell contact-mediated suppression of proliferation and interferon-gamma production in target CD4+,CD25- T cells. The induction of FoxP3 in SLE Treg cells occurred only in seropositive Patients, and was correlated with anti-DNA and IgG serum titers. Conclusion. These results suggest a new modality to reverse the functional deficit of Treg cells in SLE patients with positive autoimmune serology, and identify a new strategy to enhance immunoregulatory T cell activity in human SLE.
引用
收藏
页码:2488 / 2497
页数:10
相关论文
共 49 条
  • [1] CD4+CD25high regulatory cells in human peripheral blood
    Baecher-Allan, C
    Brown, JA
    Freeman, GJ
    Hafler, DA
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (03) : 1245 - 1253
  • [2] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
    Bielekova, B
    Goodwin, B
    Richert, N
    Cortese, I
    Kondo, T
    Afshar, G
    Gran, B
    Eaton, J
    Antel, J
    Frank, JA
    McFarland, HF
    Martin, R
    [J]. NATURE MEDICINE, 2000, 6 (10) : 1167 - 1175
  • [3] Therapeutic vaccination using CD4+ CD25+ antigen-specific regulatory T cells
    Bluestone, JA
    Tang, QZ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 : 14622 - 14626
  • [4] DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS
    BOMBARDIER, C
    GLADMAN, DD
    UROWITZ, MB
    CARON, D
    CHANG, CH
    [J]. ARTHRITIS AND RHEUMATISM, 1992, 35 (06): : 630 - 640
  • [5] Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3
    Chen, WJ
    Jin, WW
    Hardegen, N
    Lei, KJ
    Li, L
    Marinos, N
    McGrady, G
    Wahl, SM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) : 1875 - 1886
  • [6] Quantification of regulatory T cells in patients with systemic lupus erythematosus
    Crispin, JC
    Martínez, A
    Alcocer-Varela, J
    [J]. JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) : 273 - 276
  • [7] DATTA SK, 2007, CURR IMMUNOL REV, V1, P42
  • [8] Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFβ-secreting CD8+ T cell suppressors
    Hahn, BH
    Singh, RP
    La Cava, A
    Ebling, FM
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (11) : 7728 - 7737
  • [9] Cellular and molecular mechanisms of regulation of autoantibody production in lupus
    Hahn, BH
    Ebling, F
    Singh, RR
    Singh, RP
    Karpouzas, G
    La Cava, AA
    [J]. AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 433 - 441
  • [10] Hahn BH, 2001, ARTHRITIS RHEUM-US, V44, P432, DOI 10.1002/1529-0131(200102)44:2<432::AID-ANR62>3.0.CO